Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- JOURNAL OF CLINICAL HYPERTENSION22(10) · pp.1835 · 2020
- 피인용
- Web of Science 14Scopus 14
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 2.719
- ISSN
- 1524-6175
저자
- Jin, Xuan제1저자Department of Cardiology, Dong-A University Hospital, Busan, Korea
- Kim, Moo HyunDepartment of Cardiology, Dong-A University Hospital, Busan, Korea
- Han, Ki HoonDivision of Cardiology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea
- Hong, Soon JunDivision of Cardiology, Department of Cardiovascular Center, Korea University Anam Hospital, Seoul, Korea
- Ahn, Jeong-CheonDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea
- Sung, Jung-HoonDepartment of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- Cho, Jin-ManDivision of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea
- 이한철Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
- Choi, So-YeonDepartment of Cardiology, Ajou University School of Medicine, Suwon, Korea
- Lee, KyounghoonDivision of Cardiology, Gachon University Gil Medical Center, Incheon, Korea
- Kim, Woo-ShikDepartment of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea
- Rhee, Moo-YongCardiovascular Center, Dongguk University Ilsan Hospital, Goyang, Korea
- Kim, Ju HanDivision of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
- Hong, Seung PyoDivision of Cardiology, Daegu Catholic University Medical Center, Daegu, Korea
- Yoo, Byung SuDivision of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
- Cho, Eun JooDivision of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
- Lee, Jae-HwanDepartment of Cardiology in Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
- Kim, Pum-JoonDepartment of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
- Park, Chang-GyuDepartment of Internal Medicine, Korea University Guro Hospital, Seoul, Korea
- Hyon, Min SuDivision of Cardiology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
- Shin, Jin HoDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
- 이상현Division of Cardiology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea
- Sung, Ki ChulDivision of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea
- Hwang, JinyongDepartment of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea
- Kwon, KihwanDepartment of Cardiology, Ewha Womans University College of Medicine, Seoul, Korea
- Chae, In-HoCardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea
- Seo, Jeong-SookDepartment of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
- Kim, HyungseopDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
- Lee, HanaYuhan Research Institute, Yuhan Corporation, Yongin, Korea
- Cho, YoonhwaYuhan Research Institute, Yuhan Corporation, Yongin, Korea
초록
Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg at 8 weeks, and the percent changes from baseline in low-density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg at 8 weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least-Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg) groups were -19.3 (2.68) mm Hg and -6.69 (2.76) mm Hg. The difference between the two groups was significant (-12.60 (2.77) mm Hg, 95% CI -18.06 to -7.14,P < .0001). The LS Mean for the percent changes from baseline in LDL cholesterol in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg) groups were -52.45 (3.23) % and 2.68 (3.15) %. The difference between the two groups was significant (-55.13 (3.20) %, 95% CI -61.45 to -48.81,P < .0001). There were no adverse events leading to discontinuation or death. Combined administration of telmisartan/amlodipine 80/5 mg and rosuvastatin 20 mg for the treatment of hypertensive patients with dyslipidemia significantly reduces blood pressure and improves lipid control. ClinicalTrials.gov identifier: NCT03067688.
키워드
amlodipinedyslipidemiahypertensionrosuvastatintelmisartanFIXED-DOSE COMBINATIONSBLOOD-PRESSUREDOUBLE-BLINDMETAANALYSISAMLODIPINEPARTICIPANTSMULTICENTERMANAGEMENTSTATINS
식별자
- Scopus EID
- 2-s2.0-85090984421
- WoS UID
- 000569480400001



로그인
연구물 목록으로